WHO ICTRP trial
The effect of dapagliflozin on anti-atherosclerosisin and atherosclerotic…
ChiCTR2100041868 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100041868 |
|---|---|
| Public title | The effect of dapagliflozin on anti-atherosclerosisin and atherosclerotic cardiovascular disease in patients with type 2 diabetes and metabolic syndrome: a randomized controlled study |
| Scientific title | The effect of dapagliflozin on anti-atherosclerosisin and atherosclerotic cardiovascular disease in patients with type 2 diabetes and metabolic syndrome: a randomized controlled study |
| Primary sponsor | The First People's Hospital of Xuzhou |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Type 2 diabetes and metabolic syndrome |
| Interventions | Dapagliflozin group:Dapagliflozin 10 mg is to be administered orally once daily. The addition of an alternative anti-diabetic agent (excluding another SGLT2 inhibitor) is be permitted 4 weeks after randomization.;Control group:In the… |
| Registration date | Jan 8, 2021 |
| Target size | Dapagliflozin group:128;Control group:128 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: